Skip to main content

Table 3 General characteristics of Analytical studies

From: Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis

Author, year, Reference Country Sample size Variables Mean ± SD drug group Mean ± SD placebo group Drug Quality
Placebo group Drug group Before After Before After
Immunoglobulin or plasma exchange
 Barth, 2011, [31] Canada 41 QMGS 14.26 ± 4.0 10.96 ± 3.5 IVIG High
 Gajdos-1, 1997, [99] France 46 Anti-AchR ab level, nmol/L 25 ± 65 17 ± 40 IVIG Medium
 Zinman, 2007, [100] Canada 24 27 QMGS 12.3 ± 4.89 9.76 ± 4.0 12.5 ± 5.49 11.61 ± 4.5 IVIG High
SFEMG 85.2 ± 50.0 91.6 ± 37.9
 Wolfe, 2002, [101] USA 6 9 QMGS 8.5 ± 1.8 8.5 ± 3.8 11.3 ± 5.6 9.7 ± 2.7 IVIG High
SFEMG 66.9 ± 21.0 56.6 ± 17.5 115 ± 84.2 94.1 ± 10.2
MG-ADL 5.3 ± 3.8 5.0 ± 2.0 6.0 ± 3.8 3.4 ± 2.4
 Gajdos-2, 2005, [30] France 81 87 Anti-AchR ab level, nmol/L 12.0 ± 2.5 11.21 ± 14.02 10.0 ± 2.8 9.35 ± 15.07 IVIG High
 Gamez, 2019, [102] Spain 25 22 QMGS 6.1 ± 3.8 5.2 ± 2.4 6.6 ± 3.5 7.1 ± 3.5 IVIG High
Anti-AchR ab level, nmol/L 14.4 ± 8.0 16.3 ± 7.4 11.3 ± 8.5 14.4 ± 8.5
 Barnett, 2013, [103] USA 26 25 QMGS 12.2 ± 4.9 11.68 ± 4.0 12.4 ± 5.5 12.25 ± 3.5 IVIG High
 Zinman, 2008, [104] Canada 26 26 QMGS 12.5 ± 5.5 11.5 ± 4.1 12.3 ± 4.9 14.0 ± 0.71 IVIG High
 Katzberg, 2014, [105] Netherlands 24 27 QMGS 12.3 ± 3.5 10.22 ± 3.5 12.5 ± 1.9 12.09 ± 1.9 IVIG High
SFEMG 85.2 ± 3.0 76.3 ± 3.0 91.6 ± 4.1 86.3 ± 1.5
 Jacob, 2020, [106] Japan 9 9 QMGS 18.1 ± 5.84 14.0 ± 3.6 18.2 ± 5.49 16.9 ± 2.8 Eculizumab High
   MG-ADL 10.9 ± 3.37 5.6 ± 3.2 9.7 ± 2.4 7.6 ± 2.8
 Gajdos-3, 2008, [107] France 87 85 QMGS 3.9 ± 1.1 1.36 ± 0.9 4.2 ± 0.70 3.31 ± 1.2 IVIG High
 Katzberg-2, 2012, [32] Canada 24 81 QMGS 12.6 ± 3.6 12.4 ± 4.2 14.9 ± 3.2 14.4 ± 4.5 IVIG Medium
Anti-AchR ab level, μmol/L 166.2 ± 12.3 209.1 ± 11.6
SFEMG 86.6 ± 7.7 85.2 ± 6.5 122.5 ± 7.5 117.2 ± 6.3
 Howard, 2019, [108] Netherlands 12 12 QMGS 11.8 ± 5.4 8.9 ± 3.8 14.5 ± 6.3 12.4 ± 4.6 Efgartigimod High
SFEMG 8.0 ± 2.2 3.6 ± 1.6 8.0 ± 3.0 5.9 ± 3.1
Corticosteroids
 Benatar, 2016, [109] USA 6 5 QMGS 6.0 ± 0.2 3.75 ± 0.9 6.5 ± 1.8 6.45 ± 1.3 Prednisone High
 Howard, 1976, [110] USA 20 21 QMGS 8.18 ± 0.63 8.15 ± 0.32 7.97 ± 0.91 8.04 ± 0.47 Prednisone Medium
 Lindberg, 1998, [111] USA 10 9 Anti-AchR ab level, μmol/L 354 ± 290 401 ± 264 Methylprednisolone Medium
Mycophenolate
 Sanders, 2008, [112] USA 88 88 QMGS 11.3 ± 1.2 7.3 ± 1.0 11.2 ± 1.3 7.9 ± 1.4 Mycophenolate High
   MG-ADL 5.14 ± 0.77 2.71 ± 0.81 4.55 ± 0.79 2.74 ± 0.74
 Meriggioli, 2003, [21] USA 7 7 QMGS 15.86 ± 15.2 13.0 ± 10.8 16.71 ± 12.3 16.43 ± 11.2 Mycophenolate High
Anti-AchR ab level, nmol/L 9.3 ± 2.3 3.32 ± 0.62 4.39 ± 0.9 3.81 ± 1.3
SFEMG 71.54 ± 11.3 60.52 ± 13.1 70.0 ± 13.2 69.26 ± 12.5
 Wolfe, 2008, [113] USA 40 40 QMGS 12.9 ± 5.1 8.42 ± 5.1 Mycophenolate Medium
MG-ADL 6.9 ± 3.1 3.3 ± 3.3 7.2 ± 3.4 4.4 ± 3.7
Group, 2008, [114] USA 41 39 QMGS 13.3 ± 5.6 8.9 ± 5.1 12.5 ± 4.5 8.9 ± 5.0 Mycophenolate High
Anti-AchR ab level, nmol/L 13.6 ± 11.3 8.3 ± 9.5 23.0 ± 13.2 16.9 ± 10.8
MG-ADL 6.9 ± 3.1 3.3 ± 3.3 7.2 ± 3.4 4.4 ± 3.7